Infectious diseases pharmacist | Clinical Associate Professor, UGA College of Pharmacy
Joined November 2020
- Tweets238
- Following151
- Followers257
- Likes598
Daniel Chastain retweeted
Excited to announce our new Seminar on Leprosy just published online in @TheLancet! 🌍 @CUDeptMedicine
This multicontinental collaboration provides an update on key public health & clinical aspects of this curable yet stigmatized granulomatous disease
thelancet.com/journals/lance…
Daniel Chastain retweeted
Super job by my @UGAPharmacy colleague @DBChastain leading this review (FREE Open Access): Adjunctive β-lactams for Staphylococcus aureus bacteremia: a narrative review journals.sagepub.com/doi/10.…
Daniel Chastain retweeted
Suggested investigation of suspected immunosuppression*
*Also: recurrent deep abscesses, chronic diarrhoea with weight loss, recurring infections, infection requiring prolonged antibiotic therapy, persistent rash (particularly without recent antibiotic use).
doi.org/10.1016/S2213-2600(2…
Thankful to have worked with @andhen25 and @GRThompsonMD in highlighting the low rates and inconsistent prescribing of PJP prophylaxis for patients on glucocorticoids ≥2 weeks in @CIDJournal
Glucocorticoids, Concomitant Immunosuppression, and PJP Prophylaxis Among U.S. Adults
✅ Just Accepted
✍️ @DBChastain
🔗 bit.ly/4j1uAW3
Daniel Chastain retweeted
The @AJHPOfficial ID themed issue was just released and we're (@stoverkr & I) excited to slowly share a brief synopsis of the included articles in this thread.
First, a link to the full issue to browse the TOC is here: academic.oup.com/ajhp/issue/…
#idxposts @ASHPOfficial
Daniel Chastain retweeted
Thanks @ASP_PharmD
Here's a direct link to the ID themed issue:
academic.oup.com/ajhp/issue/…
I'll try and provide a brief recap on the full edition over @X soon!
@AJHPOfficial @AJHPOfficial @stoverkr
Lots of great articles in this ID-themed issue of @AJHPOfficial @ASHPOfficial, including guest editors @BBookstaver_USC & @stoverkr.
If you're into ID Rx, this issue is for you.
Great collab w/ @UGAPharmacy students Meg George & Tonisha Gaitor, @andhen25, and @DavidCluck2, examining climate change's impact on fungal infections, incl. increased virulence, resistance, & emerging pathogens! Thanks @TAInfDis! journals.sagepub.com/doi/ful…
🌍🔥 Climate change is fueling the rise of fungal infections! Warmer temps, extreme weather & shifting ecosystems are making fungi more virulent & drug-resistant. With rising host susceptibility, the threat is growing.
journals.sagepub.com/doi/ful…
Daniel Chastain retweeted
Good discussion on pros and cons of potentially shortening treatment duration for candidemia by @UGAPharmacy faculty @DBChastain. Still awaiting more data to make informed decisions on appropriate DOT. #ashp24
Daniel Chastain retweeted
Inspired on our recent trips to Peru and Zimbabwe
We have so much to learn from our Global South colleagues
#GlobalHealth
@CUDeptMedicine @E_Stenehjem @paimadhu
📚Submissions open for the collection -Case Reports from the Global South: Learning from Low- to Mid-Resource Settings
🗓️ Deadline: November 28, 2025
💡 Showcase innovation,resilience, & local expertise in resource-limited settings. @andhen25
journals.sagepub.com/topic/c…
Daniel Chastain retweeted
Looking for a PGY2 ID residency (or CC, or Peds)? Come see @UMMCPharmacy at either the SNPhA x ACCP showcase this week or at ASHP Midyear! All PGY2 programs will be at PPS!
The SNPhA x ACCP Residency Showcase - take advantage of this innovative opportunity to make purposeful connections. Learn more and register: ow.ly/7XMQ50SWfKf
@SNPhA
Daniel Chastain retweeted
Our large database analysis @TriNetX of viral and fungal infections after CAR T cell therapy is out now at @CMIJournal! With @Emily_Siegrist @andhen25 @RitaWilsonDib1 @joseandres2910 @DBChastain @chiayuchiuID et al.
@OUCollegeofMed #TxID #lymsm #mmsm
🧵
clinicalmicrobiologyandinfec…
Daniel Chastain retweeted
My beloved Cali, Colombia is hosting the 16th meeting of the Conference of the Parties to the Convention on Biological Diversity 🌿 🦠🌍
@UNBiodiversity is spotlighting how protecting our planet's biodiversity can help prevent diseases
#COP16 #GlobalHealth @CUDeptMedicine
Thanks, @hallpharms! It was a lot of fun putting these slides together and highlighting all the fantastic work being done with SAB.
This Post is from an account that no longer exists. Learn more
What a fantastic session with @andhen25 and @bryan_p_white! Appreciate @IDWeekmtg for the opportunity to watch virtually.
So excited to hear from our super ⭐️ Editor in Chief @andhen25 about optimal therapy for invasive Candidiasis 🍄 #IDWeek2024
Thank you so much @patricia_rdz_z! Appreciate you sharing the presentation.
#IDWeek2024 Biterapia en bacteriemia por Estafilococo aureus, en Camera 1 y Camera 2 origen endovascular está subrepresentado .8-39% no responden a monoterapia. En quien considerarla riesgo de Bacteremia persistente estratificar pacientes . Great talk @DBChastain
You're the best @stoverkr! Thank you so much for all your support!
Kudos to #IDWeek2024 for providing the hybrid meeting option so I could watch this 🔥🔥 session with @DBChastain and moderated by @blandman19 on the way home.
Well done, @ferraz_md! Congratulations!
A huge shoutout to the talented @ferraz_md for her inspiring poster and research on candidemia mortality differences by species at @IDWeekmtg 🌟
Your work is crucial in advancing our understanding and treatment of this serious infection. Bravo! 👏🦠
@CUDivofID @CUAnschutz
Daniel Chastain retweeted
I love these two slides on the evidence for combination therapy in persistent MRSA and MSSA bacteremia. References in footer of each slide. #IDWeek2024
Very grateful to @SAIRABT for sharing my slides from @IDWeekmtg. Exciting to see the presentation reaching a broader audience!
Thanks @CalderwoodMD for sharing my slides on this important @CIDJournal paper highlighting the diversity and longitudinal trends of SAB, with subphenotypes that impact outcomes—crucial insights for personalizing therapy
Fascinating study discussed at #IDWeek2024. Four different clinical phenotypes for S aureus bacteremia. pubmed.ncbi.nlm.nih.gov/3891… Highest mortality in A, lower mortality in B and E, microbiologic outcomes worse in C (with adjunctive rifampicin benefit seen in C).
